Assertio Therapeutics Revenue and Competitors

Location

$42.5M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Assertio Therapeutics's estimated annual revenue is currently $33M per year.(i)
  • Assertio Therapeutics's estimated revenue per employee is $228,917
  • Assertio Therapeutics's total funding is $42.5M.

Employee Data

  • Assertio Therapeutics has 144 Employees.(i)
  • Assertio Therapeutics grew their employee count by 0% last year.

Assertio Therapeutics's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
Sr. VP OperationsReveal Email/Phone
3
SVP, Commercial Pricing, Analytics, and DistributionReveal Email/Phone
4
VP, Business Development and Commercial AnalyticsReveal Email/Phone
5
Sr. VP, Commercial OperationsReveal Email/Phone
6
VP, Human ResourcesReveal Email/Phone
7
VP, FinanceReveal Email/Phone
8
SVP MedicalReveal Email/Phone
9
SVP, General CounselReveal Email/Phone
10
SVP, HR & AdministrationReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Assertio Therapeutics?

Assertio reflects an aspirational mindset that is forward thinking, energetic, and entrepreneurial in spirit. The Assertio mission of advancing patient care is reflected in our three-pillar strategy

keywords:N/A

$42.5M

Total Funding

144

Number of Employees

$33M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Assertio Therapeutics News

2022-04-17 - Global Post herpetic Neuralgia Treatment Market 2022 ...

Pfizer, Arbor Pharma, Assertio Therapeutics, Endo Pharma, Teikoku Pharma, Teva, Mylan, Hengrui Medicine,.

2022-04-17 - Global Post herpetic Neuralgia Treatment Market 2022 ...

Pfizer, Arbor Pharma, Assertio Therapeutics, Endo Pharma, Teikoku Pharma, Teva, Mylan, Hengrui Medicine,.

2022-04-17 - Assertio (NASDAQ:ASRT) Stock Rating Lowered by Zacks ...

The company's business development includes acquisitions, licensing and mergers. Assertio Holdings Inc., formerly known as Assertio Therapeutics...

2022-04-17 - Assertio (NASDAQ:ASRT) Stock Rating Lowered by Zacks ...

The company's business development includes acquisitions, licensing and mergers. Assertio Holdings Inc., formerly known as Assertio Therapeutics...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$34.8M14448%N/A
#2
$42.8M144-4%N/A
#3
$32.5M14577%N/A
#4
$23.4M147-4%N/A
#5
$23.6M148-7%N/A